Simultaneous Measurement of Arterial Transit Time, Arterial Blood Volume, and Cerebral Blood Flow Using Arterial Spin-Labeling in Patients with Alzheimer Disease

BACKGROUND AND PURPOSE: Cerebral hemodynamics abnormality in Alzheimer disease (AD) is not fully understood. Our aim was to determine whether regional hypoperfusion due to AD is associated with abnormalities in regional arterial blood volume (rABV) and regional arterial transit time (rATT) as measured by quantitative arterial spin-labeling (ASL) with multiple-delay time sampling. MATERIALS AND METHODS: Nineteen patients with AD (9 men and 10 women; mean age, 74.5 ± 8.6 years) and 22 cognitively healthy control subjects (11 men and 11 women; mean age, 72.8 ± 6.8 years) were studied by using a quantitative ASL method with multiple-delay time sampling. From the ASL data, maps of regional cerebral blood flow (rCBF), rABV, and rATT were generated. A region of hypoperfusion due to AD was determined by statistical parametric mapping (SPM) analysis. Mean rCBF, rABV, and rATT values within the hypoperfused region were compared between the AD and control groups. RESULTS: Despite the significantly lower rCBF (P = .0004) in patients with AD (27.8 ± 7.1 mL/100 g/min) in comparison with control subjects (36.7 ± 6.3 mL/100 g/min), no significant difference in rATT was observed between the control (0.48 ± 0.09 seconds) and AD (0.47 ± 0.10 seconds) groups. Mean rABV was lower in the AD group (0.22 ± 0.10%) than in the control group (0.27 ± 0.12%), though the difference did not reach the level of statistical significance. CONCLUSIONS: Our results revealed that regional hypoperfusion in AD is not associated with rATT prolongation, suggesting that the mechanism of hypoperfusion is distinct from that in cerebrovascular diseases.

[1]  B. Holman,et al.  Cerebral perfusion imaging in Alzheimer's disease. Use of single photon emission computed tomography and iofetamine hydrochloride I 123. , 1987, Archives of neurology.

[2]  Takashi Asada,et al.  Functional interactions between entorhinal cortex and posterior cingulate cortex at the very early stage of Alzheimer's disease using brain perfusion single-photon emission computed tomography , 2006, Nuclear medicine communications.

[3]  Kazunari Ishii,et al.  Demonstration of decreased posterior cingulate perfusion in mild Alzheimer's disease by means of H215O positron emission tomography , 1997, European Journal of Nuclear Medicine.

[4]  M. Raichle,et al.  Physiological responses to focal cerebral ischemia in humans , 1984, Annals of neurology.

[5]  P. Sandercock,et al.  Comparison of 10 Different Magnetic Resonance Perfusion Imaging Processing Methods in Acute Ischemic Stroke: Effect on Lesion Size, Proportion of Patients With Diffusion/Perfusion Mismatch, Clinical Scores, and Radiologic Outcomes , 2007, Stroke.

[6]  I. Lemahieu,et al.  Acetazolamide Vasoreactivity in Vascular Dementia: A Positron Emission Tomographic Study , 1999, European Neurology.

[7]  H. Barthel,et al.  Changes in local cerebral blood flow by neuroactivation and vasoactivation in patients with impaired cognitive function , 1996, European Journal of Nuclear Medicine.

[8]  S. Francis,et al.  Noninvasive measurement of arterial cerebral blood volume using look‐locker EPI and arterial spin labeling , 2007, Magnetic resonance in medicine.

[9]  Esben Thade Petersen,et al.  Model‐free arterial spin labeling quantification approach for perfusion MRI , 2006, Magnetic resonance in medicine.

[10]  N. Schuff,et al.  Human brain: reliability and reproducibility of pulsed arterial spin-labeling perfusion MR imaging. , 2005, Radiology.

[11]  E. Shimosegawa,et al.  Hemodynamic Aspects of Alzheimer's Disease , 2002, Annals of the New York Academy of Sciences.

[12]  J. Detre,et al.  Assessment of cerebral blood flow in Alzheimer's disease by spin‐labeled magnetic resonance imaging , 2000, Annals of neurology.

[13]  László Pávics,et al.  Regional cerebral blood flow single-photon emission tomography with 99mTc-HMPAO and the acetazolamide test in the evaluation of vascular and Alzheimer’s dementia , 1999, European Journal of Nuclear Medicine.

[14]  John F. Canny,et al.  A Computational Approach to Edge Detection , 1986, IEEE Transactions on Pattern Analysis and Machine Intelligence.

[15]  D. Look,et al.  Time Saving in Measurement of NMR and EPR Relaxation Times , 1970 .

[16]  N. Schuff,et al.  Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. , 2005, Radiology.

[17]  J. Meyer,et al.  Neuroimaging for differentiating vascular from Alzheimer's dementias. , 1996, Cerebrovascular and brain metabolism reviews.

[18]  M. Weiner,et al.  The effect of acetazolamide on regional cerebral blood flow in patients with Alzheimer's disease or stroke as measured by single-photon emission computed tomography. , 1989, Investigative radiology.

[19]  G Becker,et al.  Diagnostic impact of cerebral transit time in the identification of microangiopathy in dementia: A transcranial ultrasound study. , 1999, Stroke.

[20]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[21]  Donald S. Williams,et al.  Perfusion imaging , 1992, Magnetic resonance in medicine.

[22]  Joseph A Maldjian,et al.  Arterial transit time imaging with flow encoding arterial spin tagging (FEAST) , 2003, Magnetic resonance in medicine.

[23]  Hiroshi Matsuda,et al.  Role of Neuroimaging in Alzheimer's Disease, with Emphasis on Brain Perfusion SPECT* , 2007, Journal of Nuclear Medicine.

[24]  J. Hendrikse,et al.  Arterial Spin-Labeling MR Imaging Measurements of Timing Parameters in Patients with a Carotid Artery Occlusion , 2008, American Journal of Neuroradiology.

[25]  Esben Thade Petersen,et al.  Cerebral border zones between distal end branches of intracranial arteries: MR imaging. , 2008, Radiology.